Blood Products

Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics

Volumn , Issue , 2013, Pages 287-301

  Ivens, Inge A ^a   Arora, Vikram ^b  

^a BAYER CORPORATION   (United States)

^b Grifols Therapeutics Inc   (United States)

Author keywords

Blood product; Coagulation factor; IGIV; Plasma derived therapeutic; Recombinant protein

Indexed keywords

EID: 84903796629     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-394810-6.00012-5     Document Type: Chapter

References (22)

1. Cohn E.J., Strong L.E., Hughes W.L., Mulford D.J., Ashworth J.N., Melin M., Taylor H.L. Preparation and properties of serum and plasma proteins. J Am. Chem. Soc 1946, 68:459.
2. Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology Position statement on the appropriate use of intravenously administered immunoglobulin http://www.aaaai.org.
3. Novokhatny V., Jesmok G.J., Landskroner K.A., Marder V.J., Zimmerman T.P. Locally delivered plasmin: Why should it be superior to plasminogen activators for direct thrombolysis?. Trends Pharmacol Sci 2004, 25(2):72-75.
4. Marder V.J., Jahan R., Gruber T., Goyal A., Arora V. Thrombolysis with plasmin: Implications for stroke treatment. Stroke 2010, 41(Suppl. 10):S45-S49.
5. Crumrine R.C., Marder V.J., Taylor G.M., Lamanna J.C., Tsipis C.P., Novokhatny V., Scuderi P., Petteway S.R., Arora V. Safety evaluation of a recombinant plasmin derivative lacking kringles 2-5 and rt-PA in a rat model of transient ischemic stroke. Exp Transl. Stroke Med 2012, 4(1):10.
6. Plasma Protein Therapeutics Association QSEAL industry standards. Published on website http://www.pptaglobal.org.
7. HIV and the blood supply: An analysis of crisis decision making 1995, National Academy Press, Washington, DC, [online]. http://www.nap.edu/books/0309053293/html/index.html, L.B. Leveton, H.C. Sox Jr, M.A. Stoto (Eds.).
8. Cai K., Gierman T.M., Hotta J., Stenland C.J., Lee D.C., Pifat D.Y., Petteway S.R. Ensuring the biologic safety of plasma-derived therapeutic proteins: Detection, inactivation, and removal of pathogens. BioDrugs 2005, 19(2):79-96.
9. Lewis R.M., Cavagnaro J. The application of ICH S6 to the preclinical safety evaluation of plasma derivative therapeutic products. Biologicals 2010, 38:494-500.
10. Schaub S.R. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem Pharmacol 2011, 82:91-98.
11. Sørensen B., Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia Nov;2005, 11(Suppl. 1):1-6.
12. Beltrán-Miranda C.P., Khan A., Jaloma-Cruz A.R., Laffan M.A. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia Jul;2005, 11(4):326-334.
13. Øvlisen K., A.T.Kristensen A.T., Tranholm M. In vivo models of haemophilia-status on current knowledge of clinical phenotypes and therapeutic interventions. Haemophilia 2008, 14:248-259.
14. Mordenti J., Osaka G., Garcia K., Thomsen K., Licko O., Meng G. Pharmacokinetics and Interspecies Scaling of Recombinant Human Factor VIII. Tox Appl. Pharmacol 1996, 75-78.
15. Van Geffen M., van Heerde W.L. Global haemostasis assays, from bench to bedside. Thromb Res 2012, 129(6):681-687.
16. Verbruggen B., Meijer P., Nova'Kova I., van Heerde W. Diagnosis of factor VIII deficiency. Haemophilia 2008, 14(Suppl. 3):76-82.
17. Mikaelsson M., Oswaldsson U. Semin Thromb Hemost 2002, 28(3):257-264.
18. ICH S6(R1): Preclinical Safety Evaluation of Biotechnology- Derived Pharmaceuticals S6(R1); Parent Guideline dated 16 July 1997 (Addendum dated 12 June 2011 incorporated at the end of June 2011).
19. Menache D., Behre H.E., Orthner C.L., Nunez H., Anderson H.D., Triantaphyllopoulos D.C., Kosow D.P. Coagulation Factor IX concentrate: Method of preparation and assessment of potential in vivo thrombogenicity in animal models. Blood Dec;1984, 64(6):1220-1227.
20. Bodarya P.F., Eitzman D.T. Animal models of thrombosis. Curr Opin Hematol 2009, 16:342-346.
21. MacGregor I., McLaughlin L., Drummond O., Prowse C., Ferguson J. In vivo models of thrombogenic potential: Usefulness and limitations. Acta Haematol 1995, 94(Suppl. 1):18-23. discussion 24.
22. ICH M3(R2): Guidance on Nonclinical Safety Studies for the Conduct of Human Clincial Trials and Marketing Authorization for Pharmaceuticals (Current Step 4 version dated 11 June 2009).